13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • MG1 HPV

    Acronym: 

    MG1 HPV

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I Tumour Stream HPV associated cancers
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type All cancers
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream HPV associated cancers
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase I/ Ib, multicentre, open-label trial of oncolytic MG1 expressing, mutant human papilloma virus (HPV) E6 and E7 (MG1-E6E7), with adenovirus vaccine expressing mutant HPV E6 and E7 (Ad-E6E7) and atezolizumab in patients with HPV associated cancers.

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Recruitment on Hold